Login
$TRAW
$0.26 +$0.00 (0.0%) After hours

$TRAW SEC Filings

Filed On Filing
16 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Date of Report (Date of earliest event reported): November 16, 2026

16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 EFFECT
12 Nov 2026 8-K: Regulation FD Disclosure

Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID®

05 Nov 2026 D
26 Oct 2026 FORM S-1
23 Oct 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of October 23, 2026 (this “Agreement”), by and between Roth Principal Investments, LLC, a Delaware limited liability company (the “Investor”), and Traws Pharma, Inc., a Del...

20 Oct 2026 DEFA14A
20 Oct 2026 DEF 14A
08 Oct 2026 PRE 14A
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 10-Q
14 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge study

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G
12 Aug 2026 SCHEDULE 13G/A
31 Jul 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On July 29, 2026, Traws Pharma, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for...

16 Jul 2026 Form 4: Pauza Charles David, Chief Science Officer Virology

Granted 97,000 Stock Option (right to buy)

15 Jul 2026 Form 4: Cautreels Werner, Director

Granted 14,150 Stock Option (right to buy)

15 Jul 2026 Form 4: Savchuk Nikolay, Director

Granted 93,000 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support